Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
Ophthalmology 2004; 111(2):276-82O

Abstract

PURPOSE

To compare the efficacy and safety of the fixed combination of latanoprost and timolol with those of the fixed combination of dorzolamide and timolol in patients with elevated intraocular pressure (IOP).

DESIGN

Three-month, randomized, parallel group, evaluator-masked, multicenter study.

PARTICIPANTS

Patients with primary open-angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy; 253 randomized: 125 to receive a fixed combination of latanoprost 0.005% and timolol 0.5% once daily, and 128 to receive a fixed combination of dorzolamide 2% and timolol 0.5% twice daily.

METHODS

Visits were at screening (current ocular hypotensive therapy was discontinued), 2 weeks (if needed for an IOP-safety check), baseline (randomization), and after 1 and 3 months of therapy. Intraocular pressure was measured in triplicate at 8 am, 12 pm, and 4 pm at each study visit, and diurnal IOP was calculated as the mean value of these recordings. Adverse events were recorded at each visit.

MAIN OUTCOME MEASURE

The difference between treatment groups in the change in mean diurnal IOP from baseline to month 3.

RESULTS

Mean diurnal IOP levels were similar at baseline. Mean (+/- standard error of the mean) reductions in diurnal IOP from baseline to month 3 were 9.4+/-0.27 mmHg in the latanoprost/timolol fixed-combination group, versus 8.4+/-0.26 mmHg in patients receiving the dorzolamide/timolol fixed combination. The mean difference in diurnal IOP reduction between treatments was 1.00 mmHg (95% confidence interval, 0.31-1.69; P = 0.005) in favor of the latanoprost/timolol fixed combination. Both treatments generally were well tolerated.

CONCLUSIONS

The fixed combination of latanoprost and timolol was slightly more effective than that of dorzolamide and timolol in reducing mean diurnal IOP, and both treatments were generally well tolerated.

Authors+Show Affiliations

Kresge Eye Institute, Wayne State University, Detroit, Michigan, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15019375

Citation

Shin, Dong H., et al. "Efficacy and Safety of the Fixed Combinations Latanoprost/timolol Versus Dorzolamide/timolol in Patients With Elevated Intraocular Pressure." Ophthalmology, vol. 111, no. 2, 2004, pp. 276-82.
Shin DH, Feldman RM, Sheu WP, et al. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111(2):276-82.
Shin, D. H., Feldman, R. M., & Sheu, W. P. (2004). Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology, 111(2), pp. 276-82.
Shin DH, et al. Efficacy and Safety of the Fixed Combinations Latanoprost/timolol Versus Dorzolamide/timolol in Patients With Elevated Intraocular Pressure. Ophthalmology. 2004;111(2):276-82. PubMed PMID: 15019375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. AU - Shin,Dong H, AU - Feldman,Robert M, AU - Sheu,Wang-Pui, AU - ,, PY - 2002/06/26/received PY - 2003/05/14/accepted PY - 2004/3/17/pubmed PY - 2004/3/24/medline PY - 2004/3/17/entrez SP - 276 EP - 82 JF - Ophthalmology JO - Ophthalmology VL - 111 IS - 2 N2 - PURPOSE: To compare the efficacy and safety of the fixed combination of latanoprost and timolol with those of the fixed combination of dorzolamide and timolol in patients with elevated intraocular pressure (IOP). DESIGN: Three-month, randomized, parallel group, evaluator-masked, multicenter study. PARTICIPANTS: Patients with primary open-angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy; 253 randomized: 125 to receive a fixed combination of latanoprost 0.005% and timolol 0.5% once daily, and 128 to receive a fixed combination of dorzolamide 2% and timolol 0.5% twice daily. METHODS: Visits were at screening (current ocular hypotensive therapy was discontinued), 2 weeks (if needed for an IOP-safety check), baseline (randomization), and after 1 and 3 months of therapy. Intraocular pressure was measured in triplicate at 8 am, 12 pm, and 4 pm at each study visit, and diurnal IOP was calculated as the mean value of these recordings. Adverse events were recorded at each visit. MAIN OUTCOME MEASURE: The difference between treatment groups in the change in mean diurnal IOP from baseline to month 3. RESULTS: Mean diurnal IOP levels were similar at baseline. Mean (+/- standard error of the mean) reductions in diurnal IOP from baseline to month 3 were 9.4+/-0.27 mmHg in the latanoprost/timolol fixed-combination group, versus 8.4+/-0.26 mmHg in patients receiving the dorzolamide/timolol fixed combination. The mean difference in diurnal IOP reduction between treatments was 1.00 mmHg (95% confidence interval, 0.31-1.69; P = 0.005) in favor of the latanoprost/timolol fixed combination. Both treatments generally were well tolerated. CONCLUSIONS: The fixed combination of latanoprost and timolol was slightly more effective than that of dorzolamide and timolol in reducing mean diurnal IOP, and both treatments were generally well tolerated. SN - 0161-6420 UR - https://www.unboundmedicine.com/medline/citation/15019375/Efficacy_and_safety_of_the_fixed_combinations_latanoprost/timolol_versus_dorzolamide/timolol_in_patients_with_elevated_intraocular_pressure_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(03)01162-X DB - PRIME DP - Unbound Medicine ER -